Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
Dawn Bruijnzeel, Rajiv Tandon Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, USA Abstract: Antipsychotic agents, utilized for the treatment of a range of psychiatric disorders, differ substantially in terms of their pharmacology and adverse effect profiles. Inc...
Saved in:
Main Authors: | Bruijnzeel D (Author), Tandon R (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical role of brexpiprazole in depression and schizophrenia
by: Parikh NB, et al.
Published: (2017) -
Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
by: Seetasith A, et al.
Published: (2019) -
Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist’s Perspective
by: Watanabe Y, et al.
Published: (2020) -
Vortioxetine as adjunctive therapy in the treatment of schizophrenia
by: Sofia Redaelli, et al.
Published: (2022) -
Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
by: Aigbogun MS, et al.
Published: (2018)